Trials / Active Not Recruiting
Active Not RecruitingNCT04837040
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paltusotine | Paltusotine, tablets, once daily by mouth |
| DRUG | Placebo | Placebo, tablets, once daily by mouth |
Timeline
- Start date
- 2021-05-12
- Primary completion
- 2023-07-10
- Completion
- 2027-06-01
- First posted
- 2021-04-08
- Last updated
- 2026-03-02
- Results posted
- 2026-01-13
Locations
39 sites across 14 countries: United States, Argentina, Belgium, Brazil, Bulgaria, France, Hungary, Israel, Italy, Peru, Poland, Russia, Serbia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04837040. Inclusion in this directory is not an endorsement.